Paper Details

  1. Home
  2. Paper Details

Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age.

Author: AndrewsNick, AshtonLindsey, BorrowRay, EnglandAnna, FindlowHelen, GoldblattDavid, MathesonMary, MillerElizabeth, SheasbyElizabeth, SouthernJoanna, StanfordElaine, WaightPauline

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The coadministration of the combined meningococcal serogroup C conjugate (MCC)/Haemophilus influenzae type b (Hib) vaccine with pneumococcal conjugate vaccine (PCV7) and measles, mumps, and rubella (MMR) vaccine is safe and immunogenic. No adverse consequences were found when all three vaccines were given concomitantly at 12 months of age, compared to separate administration.
Paper Details　
Original Abstract of the Article :
The coadministration of the combined meningococcal serogroup C conjugate (MCC)/Haemophilus influenzae type b (Hib) vaccine with pneumococcal conjugate vaccine (PCV7) and measles, mumps, and rubella (MMR) vaccine at 12 months of age was investigated to assess the safety and immunogenicity of this reg...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3067384/

データ提供：米国国立医学図書館（NLM）

Co-administration of Vaccines for Infants

Vaccinations are a cornerstone of public health, protecting individuals from serious diseases. This study explores the safety and immunogenicity of co-administering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine (MCC/Hib) with pneumococcal conjugate vaccine (PCV7) and measles, mumps, and rubella vaccine (MMR) at 12 months of age. The researchers aimed to determine whether this combined vaccination schedule was safe and effective in eliciting an immune response.

A Quest for Efficient Vaccination

The study explores the potential of streamlining the vaccination schedule for infants, investigating the safety and efficacy of co-administering multiple vaccines. The researchers, like explorers seeking to optimize a journey, aimed to find a more efficient approach to protecting infants from a range of diseases. The study's findings suggest that co-administration of these vaccines is safe and effective, offering a potential solution for improving vaccine delivery and minimizing the number of clinic visits.

Protecting Infants with Fewer Visits

This study provides valuable insights into the safety and efficacy of co-administering multiple vaccines in infants. The researchers demonstrate that this approach is safe and effective, allowing for a streamlined vaccination schedule. This approach can help reduce the number of clinic visits and make the vaccination process more convenient for families.

Dr.Camel's Conclusion

This research, like a caravan of camels carrying precious vaccines, explores the potential of streamlining the vaccination schedule for infants. The study's findings suggest that co-administering multiple vaccines is safe and effective, offering a more efficient approach to protecting infants from a range of diseases. It's a testament to the power of research and innovation in public health, leading to better outcomes for infants and families worldwide.

Date :
  1. Date Completed 2011-06-07
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21191076

DOI: Digital Object Identifier

PMC3067384

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.